An observational study in Type 1 Diabetes (T1D) and Type 2 Diabetes, sponsored by University of Oxford. Recruiting at 4 sites in United Kingdom. Open to participants aged Up to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by University of Oxford · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom — 32 open to participants now, 41 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · United Kingdom.
Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, this one is the 27th largest by planned enrollment of the 54 observational ones that give a count, is one of 6 that started in 2024, is one of 54 observational ones, reaches primary completion later than 18 of the 40 other live ones, and was the 252nd registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →32 of the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom are open now. Recruiting first, the newest first:
Sanofi · Sites in United Kingdom, Belgium, France and 3 more countries
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 16 more countries
Ages 1–35
Imperial College London · Sites in United Kingdom
Ages 18+
SAb Biotherapeutics, Inc. · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 5–40
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: Up to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
268 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 31 · Phase 3 53 · Phase 4 18
First in 1997; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 135 is close to the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 214 interventional studies, 133 across the 54 observational. Of the 206 that completed or were terminated, 76 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 268 have an industry lead sponsor. The 10 most frequent:
University of Oxford is the lead sponsor of 813 studies on the registry; 119 are open to participants now.
University of Oxford has 7 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
14 of the studies in Diabetes Mellitus, Type 1 with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT06782568Imperial College LondonAvoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics | 2026-12-31 |
| NCT07583238University of NottinghamDiathermy On Diabetes Glucose Monitoring Effectiveness | 2027-02 |
| NCT06815081University of OxfordCapillary OGTT Study | 2027-02-28 |
| NCT07251257University of SurreyThe Seafarers' Continuous Glucose Monitoring Systems Study | 2027-03-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Type 1 diabetes (T1D) is a chronic condition, affecting 1 in 490 children under the age of 15 years. It is caused by the immune system damaging the pancreas, the organ which makes insulin. T1D has recognised stages before symptoms develop, providing an opportunity for early diagnosis, education and treatment which may delay the onset of symptoms.
Type 2 diabetes (T2D) is also a chronic condition where the body cannot make enough insulin, or cannot respond to the insulin properly. It is usually related to obesity, rather than an immune problem. It is more common in adults, but the early stages often start in childhood (up to 1 in 4 children in some clinics). Like T1D, early detection can delay onset of T2D, or even prevent it altogether.
Early diagnosis of T1D or T2D often relies on a test called the oral glucose tolerance test (OGTT), which is commonly used but not well tolerated, possibly because it requires a drip inserted into the vein, and several blood samples taken over 2-3 hours in a healthcare setting.
Our study aims to test whether we can do an OGTT using a finger-prick to test glucose, at home. We call this the 'GTT@home'. The finger-prick creates a drop of blood, which is done before and two hours after drinking a sugary drink. We will also explore whether a continuous glucose monitor (CGM), which reads glucose levels through the skin could be an alternative. We plan to recruit 90 children and young people, across two groups to assess the GTT@home.
To understand the experiences of those involved in monitoring, we will invite young people, parents and healthcare workers to take part in an interview, to understand the impact of testing to predict clinical T1D.
Group 1 will assess the accuracy of measuring glucose from a finger-prick blood test when compared to a blood test from the vein. We will recruit individuals who are having an OGTT as part of a research study, for clinical care or if they have agreed to have an OGTT for this study. Those with T1D will be invited to wear a CGM to explore its use as an additional, practical alternative.
Groups 2 and 3 will assess how well the GTT@home test works when done at home and how acceptable it is. This will only be offered to those known to be at risk of T1D.
These studies will help us to understand if the GTT@home can be used in routine care.
Cohort 1 - Children \< 18 years of age. To get a spread of glucose values, we will aim to recruit approximately equal numbers of participants with normoglycaemia, dysglycaemia and hyperglycaemia.
Cohort 1 CGM sub-study - Children \< 18 years of age, who have T1D stage 1, 2 or 3 and undergoing an OGTT in cohort 1.This sub-study will be additional and optional to cohort 1.
Cohort 2 - Children \< 18 years of age, who are identified as having stage 1, 2 or 3 T1D will be invited to take part in an OGTT at home.
Cohort 3 - Children \< 18 years of age, who are identified as having pre-T2D.
Qualitative sub-study - Young people ≥ 15 years old with T1D stage 1, 2 or recent stage 3 (up to 12 months), who have been involved in metabolic follow-up, will be invited to take part. Parents of a child (of any age) with T1D stage 1, 2 or recent stage 3 will also be invited. Healthcare professionals involved in delivering metabolic follow-up for children with diabetes antibodies will also be invited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort 1
Cohort 2
CGM sub-study
Qualitative sub-study
Cohort 3
Exclusion Criteria:
Cohort 1
Cohort 2
CGM sub-study
Qualitative sub-study
Cohort 3
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To assess the ability of the capillary OGTT to be a reliable and acceptable alternative to the standard venous OGTT in children, investigators will aim to capture a spread of glucose values across the whole diagnostic range. This will be undertaken in clinical and research settings, led by either a healthcare professional or research nurse. Children undergoing a standard venous OGTT will be invited to complete a capillary OGTT. Both venous and capillary samples will be collected at the same time. Investigators will also invite children with stage 3 (clinical) T1D to capture glucose levels in the hyperglycaemic range. These participants will receive a smaller glucose dose for their OGTT (1g/kg, max dose 75g), to attenuate their glucose rise and allow the comparison of clinically meaningful glucose values. Participants will be asked to complete a questionnaire following the OGTT to obtain information about acceptability.
In this cohort (running concurrently alongside cohort 1) investigators aim to assess the acceptability and feasibility of a capillary OGTT device in children and young people with early-stage (known stage 1 or 2) T1D. This will take place in the home of participants, with written and video instructions provided. Children known to be positive for ≥ 2 IAb will be invited to take part and will be sent a capillary OGTT test kit which will include a glucose drink, lancets and instructions (written and video). They will fast overnight (from midnight the night before, for a minimum of 8 hours) before completing a 2-hour OGTT using the test kit and instructions provided. Glucose samples will be collected at 0 and 120 minutes. Participants will be asked to complete a questionnaire following completion of the OGTT, to obtain information about acceptability.
In this sub-study investigators aim to explore the ability of CGM to be an alternative to the standard venous OGTT. A subgroup of participants in cohort 1 with known T1D (stage 1, 2 or 3) will be invited to wear a CGM sensor for up to 10 days, which will be worn during their OGTT, at home during a standard mixed meal and free-living. Whilst wearing the CGM at home, participants will be asked to consume a liquid mixed meal (Ensure Plus, 6ml/kg maximum 360ml, preceded by an 8-hour fast) and complete a 3-day food diary, by photographing the largest meal of the day to allow estimation of carbohydrate intake (not the same day as the OGTT or liquid mixed meal). Participants will then be asked to complete a questionnaire to obtain information about acceptability.
To understand the factors that contribute to uptake of monitoring offered to children at risk of type 1 diabetes, investigators will invite a small number of young people (aged 15-18) and parents to take part in a semi-structured interview. Investigators will also invite healthcare professionals involved in delivering metabolic testing as part of follow-up to take part in semi-structured interviews, to understand their views on the factors which may influence future implementation into clinical care.
In this cohort (running concurrently alongside cohort 1) we aim to assess the acceptability and feasibility of a capillary OGTT device in children with pre-clinical T2D at home. This will take place in the home of participants, with written or video instructions provided. For cohort 3, children with raised BMI (≥91st centile) and any marker of insulin resistance: HbA1c 39-47mmol, or known impaired fasting glucose (5.6 - 6.9 mmol/L), or impaired glucose tolerance (7.8 - 11.0 mmol/L), will be invited to take part. They will fast overnight (from midnight the night before, for a minimum of 8 hours) before completing a 2-hour OGTT using the test kit and instructions provided. Participants will be asked to complete a questionnaire following completion of the OGTT, to obtain information about acceptability.
To determine the agreement of capillary blood glucose levels to venous blood glucose levels during a standard OGTT
Agreement between capillary and blood glucose measures.
Time frame: From enrolment to end of study visit on day 1.
To assess the feasibility of using the capillary OGTT device in the home environment
1. Proportion of successful glucose readings at 0, 120 minutes 2. Proportion of errors/missing glucose readings 3. Proportion of adverse events
Time frame: From enrolment to end of study visit on day 1
To determine the diagnostic accuracy of capillary blood glucose levels at diagnostic thresholds
Sensitivity and specificity of capillary glucose at 5.6mmol/L, 7.0mmol/L (fasting), 11.1 mmol/L (60 min), and 7.8mmol/L and 11.1mmol/L (120 min).
Time frame: From enrolment to end of study visit on day 1.
Assess the acceptability of the capillary OGTT device
Acceptability by questionnaire (Parent +/- child), using either a standard 7-point Likert scale (1 - not painful at all, 7 - very painful) for participants aged 16 and above, or Wong Baker Faces pain scale (0 - no hurt, 10 - hurts worst) for participants aged under 16.
Time frame: From enrolment to end of study visit on day 1.
To assess the in-depth experience of participants attending study visits involving a metabolic test or assessment
Analysis of qualitative interviews from young people.
Time frame: From enrolment to end of study visit on day 1
To assess the in-depth experience of parents attending study visits with their child involving a metabolic test or assessment
Analysis of qualitative interviews from parents.
Time frame: From enrolment to end of study visit on day 1.
To assess the in-depth views of healthcare professionals involved in the delivery of a metabolic test or assessment of a child
Analysis of qualitative interviews from healthcare professionals.
Time frame: From enrolment to end of study visit on day 1.
To explore the diagnostic accuracy of CGM to define T1D stages during a standard OGTT
Sensitivity/specificity of sensor glucose levels at diagnostic thresholds.
Time frame: From enrolment to end of study visit at day 10.
To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living
Sensor glucose variability (coefficient of variation (%CV)), during home meals, across different T1D stages.
Time frame: From enrolment to end of study visit on day 10.
To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living
Sensor glucose variability (mean amplitude of glycaemic excursion (MAGE) mmol/L)), during home meals, across different T1D stages.
Time frame: From enrolment to end of study visit on day 10.
To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living
Sensor glucose variability (low blood glucose index (LBGI)), during home meals, across different T1D stages.
Time frame: From enrolment to end of study visit on day 10.
To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living
Sensor glucose variability (high blood glucose index (HBGI)), during home meals, across different T1D stages.
Time frame: From enrolment to end of study visit on day 10.
To explore CGM values at fasting and 120-minutes and its relation to OGTT measures of glucose, during a) standard liquid mixed meal, and b) free-living
Sensor glucose variability (average daily risk range (ADRR)), during home meals, across different T1D stages.
Time frame: From enrolment to end of study visit on day 10.
Plan to share: Yes — Dates of birth will not be shared, but ages (possibly grouped) will be provided.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD and supporting information will be availabile once the primary paper for the study has been published.
Access criteria: Subject to participant consent, data will be shared with other researchers for research projects that have appropriate ethical approval. Requests for access to the data will be controlled by the Data Access Committee.
Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.